HIF2A is activated in clear cell renal cell carcinoma (ccRCC) through mutations in the von Hippel-Lindau tumour suppressor gene (VHL), which under normal conditions targets HIF2A for proteosomal degradation7. This evidence concerns the gene EPAS1 and clear cell renal carcinoma.